Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
137
resultados
Última actualización
28/08/2026 [07:42:00]
Resultados 25 a 50 de 137
Resumen de: WO2018156937A1
Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.
Resumen de: US20260191892A1
0000 The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.
Resumen de: US20260193710A1
Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or postoperative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.
Resumen de: US20260193242A1
0000 The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R to R<3 >and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
0000
Resumen de: CN122326775A
The invention relates to a method for analyzing a relationship between intestinal microbiota and an emotional symptom of an IBS patient. The method comprises the following steps: determining a causal relationship between the intestinal microbiota and the emotional symptom of the IBS patient; determining that the emotional symptom is caused by reduction of abundance of A. shahii in the intestinal microbiota; determining that the emotional symptom is caused by the reduction of indole produced by metabolism of the intestinal microbiota, and the reduction of indole is caused by the reduction of abundance of A. shahii; determining that the emotional symptom is caused by the decrease of TnAse generated by the intestinal microbiota, the decrease of TnAse is caused by the decrease of abundance of A. shahii, and the decrease of indole is caused by the decrease of TnAse; determining that the emotional symptom is caused by the weakening of AhR signal transduction in the vDG of the IBS patient, and the weakening of AhR signal transduction is caused by the reduction of indole; and determining that the emotional symptoms are caused by the weakening of vDG granular cell viability and the weakening of the vDG granular cell viability is caused by the weakening of AhR signal transduction, thereby obtaining an analysis result that the intestinal microbiota regulates and controls the emotional symptoms through the A. shahii-TnAse-indole-AhR-vDG signal pathway.
Resumen de: CN122337675A
The invention provides a clinical prediction model of anal fistula occurrence probability of a Crohn disease patient and a design method, and belongs to the technical field of clinical medicine. The risk prediction model comprises: an input module receiving patient parameter indexes composed of age during diagnosis, biological agent mode switching and Monte's performance typing during primary definite diagnosis; the processing module is connected with the input module and is used for calculating the evaluation and prediction probability of the anal fistula of the patient suffering from the Crohn disease according to the following formula on the basis of the age during diagnosis, the biological agent mode switching and the Monte performance typing data during primary definite diagnosis; the output module is connected with the processing module and outputs the anal fistula risk probability, obtained by the risk prediction model, of the patient suffering from the Rohn disease. And respectively verifying the prediction model in the training set and the verification set by adopting the area under the curve of the working characteristic curve of the subject and the calibration curve so as to judge the distinction degree and the calibration degree of the prediction model. The risk of anal fistula of a patient suffering from Crohn's disease can be accurately predicted before treatment.
Resumen de: CN122337553A
The invention discloses a diagnosis and treatment path recommendation method based on IBS multi-dimensional data, and relates to the technical field of intelligent diagnosis and treatment, and the method comprises the following steps: S1, constructing an IBS treatment scheme library which comprises standardized treatment schemes corresponding to different diagnosis types and different disease severity degrees of IBS, the standardized treatment schemes at least comprise review suggestions, drug recommendation, probiotic recommendation and nursing guidance, and each treatment scheme is associated with a corresponding IBS multi-dimensional data feature threshold. According to the diagnosis and treatment path recommendation method based on the IBS multi-dimensional data, the limitation of single diagnosis data dimension in the prior art is broken through, four core dimensions of symptom data, physical sign data, laboratory examination data and medical history data of a patient are comprehensively integrated, and the symptom data is ensured to be free of omission by combining dual modes of patient autonomous filling and reporting and doctor inquiry; objectivity of physical sign data is guaranteed through professional medical equipment, laboratory inspection data are synchronously obtained from a hospital inspection system, and errors are reduced.
Resumen de: CN122337628A
The invention belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease assessment method and system.The method includes the steps that biological sample data of a target object is obtained and preprocessed to standardize index data, and the index data is obtained; and calculating multiple scores representing the individual state of the target object based on the preprocessed biological sample data, and constructing a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on the scores. According to the scheme provided by the invention, a multi-dimensional comprehensive evaluation index is constructed by integrating multiple index data, so that the pathophysiological essence of the inflammatory bowel disease can be comprehensively and accurately reflected, misdiagnosis or missed diagnosis caused by single-dimensional evaluation is effectively avoided, and the diagnosis accuracy is improved. And a non-invasive, convenient and standardized technical solution is provided for diagnosis, illness monitoring and curative effect evaluation of the inflammatory bowel disease.
Resumen de: US20260185998A1
Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m/z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and GSA×Tyr: AHA×(an anion having m/z: RMT: polarity of 160.0615:0.830: n) ratiometric biomarker.
Resumen de: CN122297639A
The invention provides an application of NUCB1 in preventing and/or treating autoimmune diseases, and particularly provides an application of an NUCB1 gene, or a protein thereof or an accelerant thereof in preparing a composition or a preparation, and the composition or the preparation is used for preventing and/or treating the autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof can significantly prevent and/or treat autoimmune diseases, especially can effectively treat systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis or Crohn's disease.
Resumen de: CN122278770A
The invention relates to a method for screening drugs for diseases closely related to unmarked G-protein coupled receptors (GPCR), in particular to an unmarked cell screening model of a GPR183 receptor and application of the unmarked cell screening model in preparation of drugs. And the unmarked cell screening model is a stably transfected cell strain CHO-K1-GPR183 with high expression of a GPR183 receptor. The GPR183 receptor stimulant compound N-demethylated nuciferine is obtained by screening through the GPR183 cell screening model established in the invention. At present, researches show that the GPR183 receptor is closely related to the occurrence and development of neuroinflammation/autoimmune diseases such as multiple sclerosis, colitis, type I diabetes and arthritis, cancers and metabolic diseases, so that a seedling compound can be provided for the development of medicines for related diseases.
Resumen de: WO2026136763A1
Provided are methods of generating a polygenic score (PGS) to identify or predict interleukin- 18 (IL- 18) driven disease in a subject, along with methods of treating subjects with various diseases and conditions, such as inflammatory bowel disease, determined to have IL- 18 driven disease or inflammasome-mediated disease based on a PGS.
Resumen de: WO2025038942A1
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Resumen de: CN122259877A
The invention discloses application of TLR8 in preparation of a product for diagnosing and treating ulcerative colitis, and belongs to the technical field of biological medicines. The invention provides an application of TLR8 in preparation of an ulcerative colitis diagnostic product, the diagnostic product is used for detecting the expression level of TLR8 in a peripheral blood sample, and the diagnostic product comprises a detection reagent, a detection kit and a detection chip; meanwhile, the invention provides application of TLR8 in preparation and/or screening of drugs for treating ulcerative colitis and application of a TLR8 inhibitor in preparation of drugs for treating or relieving ulcerative colitis. The medicine can be used for reducing the phosphorylation level of p65 in an NF-kappa B pathway by inhibiting the expression of TLR8, so that the intestinal inflammatory response is relieved. The invention clarifies the association between TLR8 and ulcerative colitis, provides a new target and detection means for the early diagnosis of ulcerative colitis, provides a new idea and drug research and development direction for the treatment of the disease, and has important clinical application value and industrialization prospect.
Resumen de: CN122229982A
The invention belongs to the technical field of marine product function application, functional food and biology, and discloses oyster oligopeptide for relieving dextran sodium sulfate (DSS) induced ulcerative colitis and a preparation method and application thereof. A DSS induced human normal colonic epithelial cell injury model is taken as a guide, oyster meat is subjected to enzymolysis, degreasing and alcohol precipitation preparation and purification to obtain oyster zymolyte, two oyster peptides are obtained through identification, bioinformatics screening and synthesis verification, and the amino acid sequences are shown as SEQ ID NO.1-2. The oyster oligopeptide has relatively strong antioxidant and anti-inflammatory activity, can effectively relieve DSS-induced NCM460 cell injury, has an effect superior to that of a positive control 5-aminosalicylic acid, and can be used for preparing medicines for relieving ulcerative colitis and foods and health-care products for adjuvant therapy of ulcerative colitis.
Resumen de: CN122245701A
The invention provides an inflammatory bowel disease subtype diagnosis model and a construction method thereof, and the diagnosis model is characterized in that an RNA editing characteristic spectrum capable of specifically distinguishing Crohn's disease and ulcerative colitis is extracted from a PBMC sample obtained by minimally invasive acquisition through a set of innovative bioinformatics flow, and the RNA editing characteristic spectrum is used for constructing the inflammatory bowel disease subtype diagnosis model. And a machine learning model is constructed and trained by using the characteristic spectrum, and finally accurate and automatic diagnosis of the IBD subtype is realized.
Resumen de: WO2026128869A1
Personalized methods of determining a reference PDE4 Inhibitor Resistance Metric for treating a future patient in need of treatment, and methods of treating a subject with an inflammatory bowel disease are provided.
Resumen de: CN122218255A
The invention discloses a combined marker for detecting Crohn's disease and application of the combined marker, and relates to the technical field of biology and medicine. The combined marker is prepared from the following components: chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, glycochenodeoxycholic acid, glycolithocholic acid, glycoursodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, taurocholic acid, tauroursodeoxycholic acid, cholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid and taurodeoxycholic acid. Adding glycylcholic acid sulfate and isolithocholic acid; the combined marker can be used for clinical diagnosis or monitoring of Crohn's disease. The metabonomics combined marker for Crohn disease diagnosis is explored, a diagnosis and identification method which is simple and convenient to detect, low in cost and easy to accept by patients is created, a traditional diagnosis mode can be well replaced, and the metabonomics combined marker has great significance in clinical diagnosis and treatment of Crohn diseases and has popularization value.
Resumen de: US20260159887A1
0000 Inflammatory bowel disease (IBD) in humans and dogs and other companion animals is characterized by infiltration of lymphocytes and macrophages into the mucosa and submucosa and clinical signs of gastrointestinal (GI) dysfunction (diarrhea, malabsorption, weight loss). Alteration of the gut environment and development of dysbiosis may allow the overgrowth of pathogenic bacteria and induction of intestinal injury and inflammation in IBD. What is needed are novel methods that allow for rapid diagnosis of IBD (and follow-up monitoring) and treatment of the disease. The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) or gastrointestinal lymphoma.
Resumen de: AU2024402123A1
Aspects of the disclosure provides composition and methods for treating a subject having inflammatory bowel disease, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: CN122150473A
The invention relates to the technical field of quality standard detection of traditional Chinese medicine preparations, in particular to a quality detection method of food retention removing and bowel relaxing capsules. According to the method for determining the characteristic chromatogram of the capsule for removing food retention and relaxing bowels, high performance liquid chromatography is adopted for determination, octadecylsilane chemically bonded silica is used as a filler, the column length is 250 mm, the inner diameter is 4.6 mm, and the particle size is 5 mu m. Acetonitrile is used as a mobile phase A, and a 0.2% phosphoric acid solution is used as a mobile phase B for elution; the flow rate is 1.0 ml per minute; the column temperature is 40 DEG C; and the detection wavelength is 265 nm. The method has the advantages of good specificity, good sample injection precision, good repeatability and good intermediate precision, and a test solution is stable at room temperature within 48 hours.
Resumen de: CN122145556A
The invention discloses a granzyme B targeting complex, a radiopharmaceutical and an imaging application of the granzyme B targeting complex in intestinal immune abnormal activity, and belongs to the field of nuclear medicine diagnosis and treatment. The complex is subjected to covalent modification, the recognition peptide and granzyme B are subjected to specific non-covalent binding firstly, then irreversible covalent linkage is triggered by means of the proximity effect, and the technical bottlenecks that an existing granzyme B probe is low in target tissue intake, short in-vivo residence time and narrow in imaging window are effectively solved. The selective retention capacity and the imaging specificity of the probe at a target part are obviously improved. The complex and the radiopharmaceutical disclosed by the invention can specifically target granzyme B released by abnormal immune activity of an intestinal diseased region, realize intestinal inflammations such as Crohn's disease and ulcerative colitis and noninvasive, dynamic and quantitative nuclear medicine imaging of aGVHD, can accurately evaluate the abnormal immune activity of the intestinal tract and monitor the treatment effect, and have good application prospects. A core tool is provided for early diagnosis and precise diagnosis and treatment of the diseases, and the kit has important clinical transformation value and application prospect.
Resumen de: CN122140776A
The invention relates to a composition for preventing or treating inflammatory bowel diseases and application thereof, belongs to the technical field of inflammatory bowel diseases, and solves the problems that in the prior art, pathogenesis of intestinal symbiotic fungi mediated inflammatory bowel diseases is unclearly explained, and a treatment means for targeting fungi related signal channels is lacked. An inflammatory bowel disease intervention scheme based on flora interaction does not exist; existing therapeutic drugs are difficult to regulate and control the immune homeostasis of intestinal tracts, amplify regulatory T cells and the like. The invention provides a composition for preventing or treating inflammatory bowel disease and application thereof, the composition comprises at least one of a Dectin-2/CARD9 antagonistic antibody or small molecule inhibitor, an antifungal agent, a lactobacillus johnsonii WXY strain and/or L-glutamic acid, and the preservation number is CGMCC No.37794. According to the present invention, the colitis can be exacerbated through the Dectin-2-CARD9 pathway, the proliferation of the regulatory T cells mediated by Lactobacillus johnsonii and L-glutamic acid can be inhibited, the change of the marker composition in the inflammatory bowel disease patients can be verified, and the diagnostic marker and the potential treatment target can be provided for the inflammatory bowel disease.
Resumen de: CN122158089A
The invention discloses an out-of-hospital grading diagnosis method based on IBS disease, and relates to the technical field of medical diagnosis, and the method comprises the following steps: S1, obtaining multi-dimensional information related to IBS disease provided by a patient in an out-of-hospital scene; s2, performing standardized preprocessing on the out-of-hospital multi-dimensional information to obtain feature data which can be input into an algorithm model; and S3, inputting the standardized feature data into a preset IBS grading diagnosis algorithm model, and outputting an IBS disease grading diagnosis result of the patient. According to the out-of-hospital grading diagnosis method based on the IBS disease, multi-dimensional out-of-hospital information is integrated, standardized preprocessing is combined to eliminate data errors, multi-feature screening and model optimization are adopted, a Roman IV diagnosis standard is referred to to train a model, meanwhile, diagnosis reliability is judged through confidence, and the misdiagnosis rate and the missed diagnosis rate are reduced; and a model iteration updating mechanism can continuously improve the diagnosis precision and adapt to the change of clinical requirements.
Nº publicación: WO2026115801A1 04/06/2026
Solicitante:
THE UNIV OF OSAKA [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u5927\u962A\u5927\u5B66
Resumen de: WO2026115801A1
Provided is an inflammatory bowel disease testing method. This inflammatory bowel disease testing method comprises (1) a step for detecting biomarkers in a biological sample collected from a subject. The biomarkers include: proHp and LRG; or proHp and CRP.
BOPI
Sede Electrónica
